Epocrates Bid Lower Following Q4 Earnings Release

Shares of Epocrates EPOC are bid lower in the after-hours following the release of the company's Q4 earnings results. Currently, shares are bid $8.20, at $10.25; they ended the regular session lower by 0.10%, at $10.25. Epocrates reported Q4 EPS of ($0.27) on revenues of $29.7 million. Q4 adjusted EBITDA was $3.1 million, while gross margin came in at 60.6%. The company said it is exploring strategic alternatives for its electronic health records offering. The company sees 2012 revenues in the range of $105-115 million. Epocrates, Inc., is a provider of mobile drug reference tools to healthcare professionals and interactive services to the healthcare industry.